BML-210 is a novel histone deacetylase (HDAC) inhibitor with putative effects on leukemia cell growth, differentiation and apoptosis. BML-210 is comparable with a well known HDAC inhibitor, phenyl butyrate, in its ability to cause cytotoxic effects dependent on exposure time and dose.